Extraordinary meeting of the Committee for Medicinal Products for Human Use (CHMP): 20 December 2021

Croatian is available via eTranslation, the European Commission's machine translation service.

Translate to Croatian | Important information about machine translation

Date

ponedjeljak, 20 prosinca 2021, Cijeli dan

Lokacija

Online
European Medicines Agency, Amsterdam, the Netherlands

This extraordinary meeting is organised to discuss the evaluation of the conditional marketing authorisation application for Nuvaxovid (also known as NVX-CoV2373), a COVID-19 vaccine developed by Novavax.

EMA will communicate on the outcome of the meeting. 

The Committee for Medicinal Products for Human Use (CHMP) is responsible for preparing the European Medicines Agency's opinions on all questions concerning human medicines.

Share this page